Mini Oral Abstract Session
MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial

https://doi.org/10.1016/j.jtho.2016.11.466Get rights and content
Under an Elsevier user license
open archive

Cited by (0)